Mechanistic Modeling of In Vitro Skin Permeation and Extrapolation to In Vivo for Topically Applied Metronidazole Drug Products Using a Physiologically Based Pharmacokinetic Model
- PMID: 35969125
- DOI: 10.1021/acs.molpharmaceut.2c00229
Mechanistic Modeling of In Vitro Skin Permeation and Extrapolation to In Vivo for Topically Applied Metronidazole Drug Products Using a Physiologically Based Pharmacokinetic Model
Abstract
Physiologically based pharmacokinetic (PBPK) modeling has increasingly been employed in dermal drug development and regulatory assessment, providing a framework to integrate relevant information including drug and drug product attributes, skin physiology parameters, and population variability. The current study aimed to develop a stepwise modeling workflow with knowledge gained from modeling in vitro skin permeation testing (IVPT) to describe in vivo exposure of metronidazole locally in the stratum corneum following topical application of complex semisolid drug products. The initial PBPK model of metronidazole in vitro skin permeation was developed using infinite and finite dose aqueous metronidazole solution. Parameters such as stratum corneum lipid-water partition coefficient (Ksclip/water) and stratum corneum lipid diffusion coefficient (Dsclip) of metronidazole were optimized using IVPT data from simple aqueous solutions (infinite) and MetroGel (10 mg/cm2 dose application), respectively. The optimized model, when parameterized with physical and structural characteristics of the drug products, was able to accurately predict the mean cumulative amount permeated (cm2/h) and flux (μg/cm2/h) profiles of metronidazole following application of different doses of MetroGel and MetroCream. Thus, the model was able to capture the impact of differences in drug product microstructure and metamorphosis of the dosage form on in vitro metronidazole permeation. The PBPK model informed by IVPT study data was able to predict the metronidazole amount in the stratum corneum as reported in clinical studies. In summary, the proposed model provides an enhanced understanding of the potential impact of drug product attributes in influencing in vitro skin permeation of metronidazole. Key kinetic parameters derived from modeling the metronidazole IVPT data improved the predictions of the developed PBPK model of in vivo local metronidazole concentrations in the stratum corneum. Overall, this work improves our confidence in the proposed workflow that accounts for drug product attributes and utilizes IVPT data toward improving predictions from advanced modeling and simulation tools.
Keywords: IVPT; PBPK model; complex semisolid formulations; dermal absorption; in vitro in vivo extrapolation; mechanistic modeling.
Similar articles
-
A Comparative Evaluation of Desoximetasone Cream and Ointment Formulations Using Experiments and In Silico Modeling.Int J Mol Sci. 2023 Oct 12;24(20):15118. doi: 10.3390/ijms242015118. Int J Mol Sci. 2023. PMID: 37894801 Free PMC article.
-
Towards the understanding of the IVPT results variability-Development, verification and validation of the PBPK model of caffeine in vitro human skin permeation.Eur J Pharm Sci. 2025 Jan 1;204:106943. doi: 10.1016/j.ejps.2024.106943. Epub 2024 Oct 20. Eur J Pharm Sci. 2025. PMID: 39437978
-
Relating transdermal delivery plasma pharmacokinetics with in vitro permeation test (IVPT) findings using diffusion and compartment-in-series models.J Control Release. 2021 Jun 10;334:37-51. doi: 10.1016/j.jconrel.2021.04.010. Epub 2021 Apr 20. J Control Release. 2021. PMID: 33857564
-
Structure of the skin barrier and its modulation by vesicular formulations.Prog Lipid Res. 2003 Jan;42(1):1-36. doi: 10.1016/s0163-7827(02)00028-0. Prog Lipid Res. 2003. PMID: 12467638 Review.
-
In vitro permeation testing for the evaluation of drug delivery to the skin.Eur J Pharm Sci. 2024 Oct 1;201:106873. doi: 10.1016/j.ejps.2024.106873. Epub 2024 Aug 8. Eur J Pharm Sci. 2024. PMID: 39121921 Review.
Cited by
-
Evaluation of in vitro Skin Permeation of Clascoterone From Clascoterone Topical Cream, 1% (w/w).AAPS PharmSciTech. 2024 Aug 13;25(6):186. doi: 10.1208/s12249-024-02887-7. AAPS PharmSciTech. 2024. PMID: 39138712
-
A mechanistic physiologically based model to assess the effect of study design and modified physiology on formulation safe space for virtual bioequivalence of dermatological drug products.Front Pharmacol. 2022 Dec 1;13:1007496. doi: 10.3389/fphar.2022.1007496. eCollection 2022. Front Pharmacol. 2022. PMID: 36532731 Free PMC article.
-
Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary.AAPS J. 2023 Oct 2;25(6):96. doi: 10.1208/s12248-023-00862-x. AAPS J. 2023. PMID: 37783902
-
Metamorphosis of Topical Semisolid Products-Understanding the Role of Rheological Properties in Drug Permeation under the "in Use" Condition.Pharmaceutics. 2023 Jun 11;15(6):1707. doi: 10.3390/pharmaceutics15061707. Pharmaceutics. 2023. PMID: 37376155 Free PMC article.
-
Topical Semisolid Products-Understanding the Impact of Metamorphosis on Skin Penetration and Physicochemical Properties.Pharmaceutics. 2022 Nov 17;14(11):2487. doi: 10.3390/pharmaceutics14112487. Pharmaceutics. 2022. PMID: 36432678 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources